Earnings ·
Reports Q3 revenue of $48.3M, updates full-year guidance to $206-$210M
TMCITreace Medical Concepts, Inc.
Treace Medical Concepts reported third-quarter 2026 revenue of $48.3 million, a 4% decline from the prior year period, driven by a shift toward lower-priced minimally invasive products and reduced bunion kit volumes. The company posted a net loss of $12.6 million, an improvement of 23% compared to $16.3 million in Q3 2025, while Adjusted EBITDA turned positive at $0.3 million versus a $2.6 million loss previously. Year-to-date cash usage decreased by 53%, or $9.7 million, leaving the company with $39.8 million in liquidity. Management updated its full-year 2026 revenue guidance to $206-$210 million and narrowed its Adjusted EBITDA loss expectation to $1.0-$2.0 million. Treace Medical Concepts is a medical technology company specializing in surgical treatments for bunions and foot and ankle conditions.